Click on headlines below to download research

Ipsen deal de-risks the strategy
IRLAB Therapeutics | 12/08/2021

IRLAB Therapeutics has made substantial progress year to date with the mesdopetam (IRL790) global licensing deal with Ipsen. By partnering its lead asset…

Global licensing deal for mesdopetam
IRLAB Therapeutics | 16/07/2021

IRLAB has signed an exclusive global licensing agreement with Ipsen worth up to $363m for its lead asset, mesdopetam, which is currently in a Phase IIb/III…

Focused on novel Parkinson’s disease treatments
IRLAB Therapeutics | 02/06/2021

IRLAB Therapeutics is focused on developing novel, potential first-in-class treatments for the symptoms of Parkinson’s disease (PD). PD is a complex…